• by bcarlson@marketresearch.com
  • September 23 2014
  • proteomics

In Proteomics Market, Desire For New Therapies Meets Reality of Research Spending

In Proteomics Market, Desire For New Therapies Meets Reality of Research Spending

 There’s a lot of interest in identification and validation of novel biomarkers that may represent potential drug targets or may lead to novel diagnostic tests     As detailed in our complete study of the proteomics market, researchers are looking to proteomics for these discoveries.  Proteomics is the study of proteins, including the study of the structure and function of proteins.  This includes the study of which proteins are expressed, when and where they are expressed, structure of proteins, roles of proteins, and interactions of proteins.   Many drug targets are proteins, and proteomics is an important tool for identification and characterization of novel drug targets.  In addition, proteomics is an important tool for the identification of novel biomarkers and biomarker panels to meet unmet needs for diagnosis of diseases and determining the best treatment for individual patients (personalized medicine).

 A major issue for researchers in the non-profit sector has been the lack of growth, and actual cutbacks, in available funding for research grants.  Cutbacks in research results in reduced spending on instruments and reagents used in research.

Funding has also been an issue in the for-profit sector.  According to the Pharmaceutical Research and Manufacturers of America (PhRMA) 2014 industry report, the amount spend by PhRMA member companies on R&D actually decreased in 2008, 2009, and 2011.  However, in 2013 compared to 2012, spending on R&D did increase 6.9% in the United States and 3.0% globally.  While this is positive, pharmaceutical companies are expected to continue to experience financial pressures on their R&D budgets.

Another major issue for companies marketing to researchers in either academia or industry is competition.  As demonstrated by the many companies discussed and profiled in the report, major segments of the proteomics market (such as mass spectrometry, chromatography, microarrays, and so forth) are quite competitive.